Press Releases Archives - Page 2 of 3

Recombinetics Launches TARGET-TB with Researchers in the Republic of Ireland and Northern Ireland to Develop Genome Editing Solutions for Bovine Tuberculosis

Research aims to reduce the public health risk and financial costs associated with this disease Recombinetics announced today the launch of TARGET-TB, a tripartite collaborative research project with University College Dublin in the Republic of Ireland and Queen’s University Belfast in Northern Ireland to combat Mycobacterium bovis (M. bovis) infection, [...]

Recombinetics Launches TARGET-TB with Researchers in the Republic of Ireland and Northern Ireland to Develop Genome Editing Solutions for Bovine TuberculosisAdam Davies2018-10-05T18:21:36-05:00

Recombinetics Announces New Board of Directors with Representatives from a Series A Strategic Investor: Gundersen Health System

Recombinetics today announced its new board of directors following this week’s completion of a $34 million Series A financing round. Gundersen Health System, a physician-led, not-for-profit healthcare system with locations in Wisconsin, Minnesota and Iowa, led the round as a strategic investor and now has three representatives on Recombinetics’ Board. [...]

Recombinetics Announces New Board of Directors with Representatives from a Series A Strategic Investor: Gundersen Health SystemAdam Davies2018-08-24T12:00:55-05:00

Recombinetics Closes $34 Million in Series A Funding

Recombinetics, a pioneer in gene-editing solutions for human health and animal agriculture, today announced the completion of a $34 million Series A financing round. “We’re pleased to announce the successful completion of our Series A Round,” said Tammy Lee, President and CEO of Recombinetics. “This financing will allow us to [...]

Recombinetics Closes $34 Million in Series A FundingAdam Davies2022-02-28T09:20:54-06:00

Recombinetics and Semex Form Alliance to Improve Animal Well-being

Precision Breeding Partnership to Eliminate the Need to Dehorn Cattle Recombinetics has formed an alliance with Semex, a Canadian-based, farmer-owned cattle genetics organization, to implement a precision breeding program that improves animal health and well-being through hornless dairy cattle genetics. The dehorning of calves is a routine procedure, designed to [...]

Recombinetics and Semex Form Alliance to Improve Animal Well-beingAdam Davies2018-05-29T08:00:52-05:00

Jim Kilman Elected to Recombinetics Board of Directors; Dr. Robert Montgomery Selected as Lead Strategist for Regenerative Medicine Advisory Board

New York-based Expertise Added for Capital Raise and Financing Strategies and Regenerative Medicine Organ Development and Transplantation Program ST. PAUL, Minn. Recombinetics (RCI), a pioneer in gene editing solutions for human health and animal agriculture, today announced two new appointments to its governance and strategic advisory boards. “The addition of [...]

Jim Kilman Elected to Recombinetics Board of Directors; Dr. Robert Montgomery Selected as Lead Strategist for Regenerative Medicine Advisory BoardAdam Davies2018-01-17T21:41:43-06:00

Recombinetics and Children’s Minnesota Collaborate to Develop Customized Swine Medical Model of Phenylketonuria

Recombinetics today announced a multi-year, exclusive collaborative research and development agreement with Children’s Minnesota, the seventh largest pediatric healthcare system in the country, to produce the first-ever large animal model of Phenylketonuria (PKU). PKU is one of the most common inborn errors of metabolism with a cumulative incidence of approximately [...]

Recombinetics and Children’s Minnesota Collaborate to Develop Customized Swine Medical Model of PhenylketonuriaIT ADMIN2017-08-10T20:41:56-05:00

RCI Names Dr. Mitchell Abrahamsen as EVP & CCO

Recombinetics (RCI) announced that Dr. Mitchell Abrahamsen has joined RCI as Executive Vice President and Chief Commercial Officer. Dr. Abrahamsen will lead product and business development efforts for RCI and its subsidiaries that are commercializing gene-edited animal models for biomedical and agricultural use, Acceligen and Surrogen. Abrahamsen will also continue to [...]

RCI Names Dr. Mitchell Abrahamsen as EVP & CCOIT ADMIN2017-07-07T14:07:48-05:00

Recombinetics Announces Major Advancements in the Development of a Novel Swine Model of Neurofibromatosis Type 1

Recombinetics announced the development of the first-of-their-kind gene-edited swine models for Neurofibromatosis Type 1 (NF1). Partially funded by the Children’s Tumor Foundation, and in collaboration with the University of Minnesota, these models are for use in preclinical safety and efficacy testing of therapeutics for this debilitating genetic disease affecting 1 [...]

Recombinetics Announces Major Advancements in the Development of a Novel Swine Model of Neurofibromatosis Type 1Adam Davies2017-05-31T16:06:40-05:00

Recombinetics’ Co-Founder Receives Award for “Impact” on Global Society

We couldn't be prouder of our co-founder, Dr. Perry Hackett, who was recognized by his research peers at University of Minnesota's Inventor Recognition Event in the "Impact" category. This award is given to the "researcher whose innovation has most positively and most broadly impacted quality of life. The innovation's impact [...]

Recombinetics’ Co-Founder Receives Award for “Impact” on Global SocietyAdam Davies2017-03-29T15:05:24-05:00

Recombinetics Awarded Wide-Ranging Chinese Patent for Gene-Edited Livestock

Recombinetics announced today that the Chinese Patent Office has issued ZL201280020439.X covering methods of making livestock with alleles from other breeds without meiotic recombination. The issued claims are not limited to a specific gene-editing tool. Specifically, the issued Chinese patent ZL201280020439.X includes a breeding method that can quickly introgress a [...]

Recombinetics Awarded Wide-Ranging Chinese Patent for Gene-Edited LivestockAdam Davies2017-03-27T14:53:18-05:00